Study guide
4.1 Polypharmacy Identification & Medication Review
ANCC Gerontological Nursing Certification GERO-BC
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the GERO-BC Exam 1.2 Eligibility, Fees, Scoring & Testing 1.3 How to Study for GERO-BC
2 Assessment Tools: Physical & Psychosocial
2.1 Fall, Depression & Pressure-Injury Risk Tools 2.2 Cognitive Assessment Tools (MMSE, MoCA, SLUMS, CAM) 2.3 Functional (ADL/IADL) & Pain Assessment
3 Social Determinants & Care Context
3.1 Social Determinants of Health in Aging 3.2 Caregiver & Support-System Assessment 3.3 Living Environment & Access Barriers
4 Pharmacotherapy Assessment
4.1 Polypharmacy Identification & Medication Review 4.2 Drug Interactions in Older Adults 4.3 Pharmacokinetic Changes with Aging
5 Aging Physiology & Clinical Findings
5.1 Sensory & Neurological Aging Changes 5.2 Circulatory & Cardiopulmonary Aging 5.3 Distinguishing Normal Aging from Pathology
6 Risk Factor Identification
6.1 Cognitive Impairment Risk Recognition 6.2 Non-Adherence Risk Factors 6.3 Elder Abuse & Neglect Screening
7 Evidence-Based Interventions
7.1 Evidence-Based Interventions & Expected Outcomes 7.2 Chronic Disease Management in Older Adults 7.3 Delirium Prevention & Dementia Care 7.4 Depression Care & Palliative/Hospice Care
8 Medications, Beers Criteria & Contraindications
8.1 Beers Criteria Essentials 8.2 Dosage & Route Modifications for Older Adults 8.3 Food, Drug & Herbal Contraindications
9 Care Planning & Prioritization
9.1 Nursing Diagnosis & Problem-List Evaluation 9.2 Person-Centered Care Planning 9.3 Outcome Evaluation & Plan Revision
10 Safety & Therapeutic Environment
10.1 Fall Prevention Interventions 10.2 Restraint Alternatives, Infection Control & Skin Integrity 10.3 Therapeutic Environment & Milieu Management 10.4 Wound Care Essentials for Older Adults
11 Care Coordination Across the Continuum
11.1 Transitions of Care 11.2 Case Management & Community Resources 11.3 Caregiver Support Systems
12 Theories, Prevention & Health Promotion
12.1 Theoretical Frameworks in Gerontology 12.2 Disease Prevention & Screenings 12.3 Immunizations & Preventive Care for Older Adults 12.4 Self-Management & Health Promotion Strategies
13 Communication & Adult Learning
13.1 Principles of Adult Learning 13.2 Communication Barriers & Adaptations 13.3 Patient & Family Education
14 Diversity, Ethics & Legal Practice
14.1 DEI & Older-Adult Subpopulations 14.2 Advance Directives & Surrogate Decision-Making 14.3 Ethics, Advocacy & Scope of Practice 14.4 Capacity & Informed Consent
15 Regulation, QI & Technology
15.1 CMS & Regulatory Compliance 15.2 Quality Improvement in Gerontological Settings 15.3 EHR & Documentation Standards 15.4 Telehealth, Remote Monitoring & Hospital-at-Home
4.1 Polypharmacy Identification & Medication Review
Key Takeaways Explain This Topic AI
Polypharmacy is commonly defined as use of five or more medications; inappropriate polypharmacy includes unnecessary, duplicative, or high-risk drugs regardless of count
A structured medication review reconciles prescribed, OTC, herbal, and shared/borrowed drugs with indications, doses, adherence, and adverse effects
Brown-bag reviews and pharmacy fill histories uncover discrepancies that patient recall alone misses
Deprescribing assessment identifies candidates for taper or stop when risk outweighs benefit or the indication is obsolete
GERO-BC assessment links medication findings to falls, delirium, GI bleeding, hypoglycemia, and other geriatric syndromes
Last updated: August 2026
Why Pharmacotherapy Assessment Matters
Medication-related harm is one of the most modifiable risks in older adult care. For GERO-BC, pharmacotherapy assessment (TCO I-A-3) means systematically identifying what the older adult is actually taking, whether each drug still has a clear indication, and how the regimen contributes to current findings—falls, confusion, anorexia, incontinence, or unexplained decline. Assessment precedes Beers-based prescribing decisions (covered later); the nurse’s job here is to gather a complete, accurate picture and recognize red flags.
Defining Polypharmacy
Polypharmacy is most often operationalized as concurrent use of five or more medications . Numeric thresholds alone are incomplete: an older adult on four high-risk agents may be more endangered than someone on six well-indicated, carefully monitored drugs. Distinguish:
- Concept Meaning Assessment cue
- Numeric polypharmacy ≥5 concurrent medications Count all scheduled + frequent PRN agents
Inappropriate polypharmacy Unnecessary, duplicative, contraindicated, or mismatched to goals Drug without indication; two drugs from same class
Hyperpolypharmacy Often ≥10 medications High complexity, adherence risk, cascade risk
Prescribing cascade New drug treats adverse effect of another Anticholinergic → urinary retention → anticholinergic for bladder
Prescribing cascades are high-yield for the exam: an adverse drug effect is misread as a new disease, and another medication is added. Classic patterns include calcium-channel-blocker edema treated with a diuretic, NSAID-related hypertension treated with another antihypertensive, and dopamine-agonist or antipsychotic effects treated with anticholinergics.
Sources of the Medication List
Older adults often have fragmented regimens across specialists, retail pharmacies, mail-order, hospital discharge lists, and family caregivers. A best-possible medication history includes:
- Patient and caregiver interview — name, dose, frequency, route, and purpose in the person’s own words
- Brown-bag review — bring all bottles, blister packs, samples, inhalers, eye drops, patches, and injectables
- OTC and complementary products — analgesics, sleep aids, antacids, vitamins, herbals, CBD, topical agents
- Pharmacy fill history / EHR reconciliation — compare prescribed vs. filled vs. taken
- Shared or borrowed medications — common in households and assisted living social networks
- Recently stopped drugs — residual effects and rebound (e.g., beta-blocker, benzodiazepine, SSRI)
Ask specifically about as-needed use frequency. A PRN opioid, benzodiazepine, or NSAID used daily is functionally a chronic medication and must be assessed for cumulative risk.
Structured Medication Review Steps
Use a consistent sequence so nothing is skipped:
- Reconcile — build one active list from all sources; flag discrepancies
- Match indication — for each drug, confirm the condition still exists and the drug addresses it
Check dose and duration — age-adjusted dosing, renal adjustment needs, time-limited drugs still running indefinitely
Assess adherence and administration — missed doses, crushing issues, inhaler technique, timing with meals
Screen adverse effects and geriatric syndromes — falls, delirium, constipation, dry mouth, orthostasis, bleeding, hypoglycemia
- Identify high-risk combinations — see Section 4.2; note for collaborative deprescribing
- Document and communicate — discrepancies, patient goals, and recommendations to the prescriber team
- Adherence vs. Intentional Nonuse
Do not label every missed dose as “noncompliance.” Explore cost, complexity (pill burden, multiple daily dosing), cognitive impairment, dysphagia, fear of side effects, religious fasting, and conflicting advice from multiple clinicians. Cost-related nonadherence and regimen complexity are assessment findings that drive care planning—not moral failures.
High-Yield Assessment Findings Linked to Medications
Clinical finding Medication-related considerations
New or worse falls Sedatives, antipsychotics, opioids, anticholinergics, antihypertensives (orthostasis), hypoglycemia
- Acute confusion / delirium Anticholinergics, benzodiazepines, opioids, corticosteroids, withdrawal states
- GI bleed / anemia NSAIDs, anticoagulants, antiplatelets, SSRIs (additive bleed risk)
- Constipation / urinary retention Opioids, anticholinergics, calcium-channel blockers
- Hyponatremia Thiazides, SSRIs/SNRIs
- Bradycardia / syncope Beta-blockers, non-DHP calcium-channel blockers, digoxin, amiodarone
When assessment reveals polypharmacy plus a geriatric syndrome, treat the medication list as a primary differential contributor—not an afterthought.
Deprescribing as an Assessment Outcome
Deprescribing is the supervised reduction or stop of medications when harms outweigh benefits or goals of care have changed. Assessment identifies candidates (e.g., long-term PPI without indication, duplicate anticholinergics, muscle relaxants for chronic nonspecific pain). Actual taper plans belong to collaborative practice; the GERO-BC nurse documents rationale, monitors withdrawal risk, and educates the patient and caregiver.
Special Populations and Settings
Medication review intensity should match setting and vulnerability:
Hospital/SNF admission or transfer: Highest discrepancy risk—reconcile within institutional policy time frames and before the first dose whenever possible
Home health and primary care: Reassess after any ED visit, specialist appointment, or new symptom cluster
Cognitive impairment: Prefer caregiver/proxy + pharmacy fill data; observe pillbox organization and leftover counts
End-of-life / changing goals: Preventive agents with long time-to-benefit (e.g., some primary-prevention therapies) become deprescribing candidates when comfort is the priority
Document who manages medications day to day, literacy/language needs, and whether blister packs or pharmacy synchronization are already in use. These details turn a static drug list into an actionable assessment.
Communication Pearls for the Exam
Frame findings as clinical safety issues: “Three anticholinergic agents plus new constipation and urinary retention” is more actionable than “patient is on too many meds.” Tie each concern to an observed syndrome, a missing indication, or a cascade hypothesis so the interprofessional team can act.
Exam tip: Polypharmacy identification is not a simple pill count. The tested skill is reconciling all sources, linking drugs to syndromes, spotting cascades, and framing deprescribing opportunities within person-centered goals.